Linden Thomson, Sara Torrecilla, Healthcare
Biotechnology in 2026: innovation with selectivity
After a stronger 2025, biotechnology entered 2026 on firm footing. Innovation remains robust, valuations are still supportive and investor interest is improving. In a selective market, Candriam focuses on differentiated assets, commercial potential and disciplined portfolio construction.